Abstract
This study was undertaken to evaluate selenium (Se) and glutathione peroxidase (GPX) status in patients with newly diagnosed acute myeloid leukemia (AML) before and after induction therapy. Twenty-five patients with newly diagnosed AML and 15 healthy age- and sex-matched control subjects were included in this study. Serum Se level by the graphite furnace atomic absorption spectrometric technique and GPX activity by an adaptation of Beutler method was performed for the patients before and after receiving the induction therapy. Serum Se level was significantly lower in patients with AML versus control subjects (63.1 +/- 8.8 versus 77 +/- 8.8 A mu g/L before therapy with a P value < 0.01 and 69 A +/- 6.8 versus 77 A +/- 8.8 A mu g/L after therapy with a P value < 0.01).GPX activity was significantly lower in patients with AML versus control subjects (1.6 A +/- 0.4 versus 3.4 A +/- 0.7 A mu/g protein pretreatment with a P value < 0.01and 1.9 A +/- 0.6 versus 3.4 A +/- 0.7 A mu/g protein post induction treatment with P value < 0.01).Se level and GPX activity significantly increased in AML patients after treatment. Patients who accomplished complete remission after induction harbored significantly higher Se levels than resistant patients before and after treatment. There was no significant correlation between serum Se level and GPX activity. Decreased Se level and reduced GPX activity in AML patients support the association of carcinogenesis and subnormal Se states.